MX380263B - Procesos para producir brivaracetam. - Google Patents

Procesos para producir brivaracetam.

Info

Publication number
MX380263B
MX380263B MX2017015133A MX2017015133A MX380263B MX 380263 B MX380263 B MX 380263B MX 2017015133 A MX2017015133 A MX 2017015133A MX 2017015133 A MX2017015133 A MX 2017015133A MX 380263 B MX380263 B MX 380263B
Authority
MX
Mexico
Prior art keywords
brivaracetam
processes
producing
provides
present
Prior art date
Application number
MX2017015133A
Other languages
English (en)
Spanish (es)
Other versions
MX2017015133A (es
Inventor
Peng Wang
Pixu Li
Qiang Wei
Yuanhua Liu
Original Assignee
Suzhou Pengxu Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57394289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX380263(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201510271449.6A external-priority patent/CN106279074B/zh
Priority claimed from CN201510430387.9A external-priority patent/CN106365986B/zh
Priority claimed from CN201510648574.4A external-priority patent/CN106432030B/zh
Application filed by Suzhou Pengxu Pharmatech Co Ltd filed Critical Suzhou Pengxu Pharmatech Co Ltd
Publication of MX2017015133A publication Critical patent/MX2017015133A/es
Publication of MX380263B publication Critical patent/MX380263B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/06Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms
    • C07C209/08Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/14Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19Acids containing three or more carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/38Acyl halides
    • C07C53/46Acyl halides containing halogen outside the carbonyl halide group
    • C07C53/50Acyl halides containing halogen outside the carbonyl halide group of acids containing three or more carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62Halogen-containing esters
    • C07C69/63Halogen-containing esters of saturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C71/00Esters of oxyacids of halogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
MX2017015133A 2015-05-25 2016-05-24 Procesos para producir brivaracetam. MX380263B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510271449.6A CN106279074B (zh) 2015-05-25 2015-05-25 一种化合物及其制备方法和在合成布瓦西坦中的用途
CN201510430387.9A CN106365986B (zh) 2015-07-21 2015-07-21 化合物及其制备方法和在合成布瓦西坦中的用途
CN201510648574.4A CN106432030B (zh) 2015-10-10 2015-10-10 布瓦西坦的一种制备方法
CN201610099672 2016-02-24
PCT/US2016/033965 WO2016191435A1 (en) 2015-05-25 2016-05-24 Processes to produce brivaracetam

Publications (2)

Publication Number Publication Date
MX2017015133A MX2017015133A (es) 2018-08-01
MX380263B true MX380263B (es) 2025-03-12

Family

ID=57394289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015133A MX380263B (es) 2015-05-25 2016-05-24 Procesos para producir brivaracetam.

Country Status (13)

Country Link
US (3) US10221134B2 (enExample)
EP (1) EP3302441B1 (enExample)
JP (1) JP6872500B2 (enExample)
KR (1) KR102630456B1 (enExample)
BR (1) BR112017025266A2 (enExample)
CA (1) CA2984832A1 (enExample)
ES (1) ES2965746T3 (enExample)
HR (1) HRP20240027T1 (enExample)
HU (1) HUE064612T2 (enExample)
IL (1) IL255880B (enExample)
MX (1) MX380263B (enExample)
PL (1) PL3302441T3 (enExample)
WO (1) WO2016191435A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984832A1 (en) 2015-05-25 2016-12-01 Esteve Quimica S.A. Processes to produce brivaracetam
CN107056643A (zh) * 2017-03-01 2017-08-18 苏州鹏旭医药科技有限公司 一种化合物的晶型a及其制备纯化方法
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN108503573B (zh) * 2017-02-24 2019-11-22 北京艾百诺医药股份有限公司 一种布瓦西坦的新的制备方法
CN108503609B (zh) * 2017-02-24 2019-12-24 北京艾百诺医药股份有限公司 一种制备光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的方法
CN108689903B (zh) * 2017-04-06 2019-12-24 北京艾百诺医药股份有限公司 一种布瓦西坦的新的制备方法
WO2018220646A1 (en) * 2017-05-29 2018-12-06 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereof
WO2019087172A1 (en) * 2017-12-19 2019-05-09 Glenmark Pharmaceuticals Limited Process for preparation of brivaracetam
CN108409557A (zh) * 2018-05-17 2018-08-17 丽珠集团新北江制药股份有限公司 布瓦西坦新中间体及其合成方法和应用
IT201800006320A1 (it) * 2018-06-14 2019-12-14 Processo per la sintesi asimmetrica di (r)-4-propildiidrofuran-2(3h)-one
CN110615744B (zh) * 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
JP7117796B2 (ja) * 2018-06-22 2022-08-15 福建▲海▼西新▲薬▼▲創▼制有限公司 化合物並びにブリバラセタム(Brivaracetam)の中間体及び原薬の合成におけるその用途
WO2020148787A1 (en) * 2019-01-17 2020-07-23 Clininvent Research Pvt. Ltd. Enantioselective synthesis of brivaracetam and intermediates thereof
CN112110843A (zh) * 2019-06-20 2020-12-22 北京万全德众医药生物技术有限公司 一种布瓦西坦的新制备方法
WO2021260721A1 (en) * 2020-06-23 2021-12-30 Clininvent Research Pvt. Ltd. A new cost effective and scalable process for synthesizing pure brivaracetam
ES3032398T3 (en) 2020-12-14 2025-07-18 Alivus Life Sciences Ltd Process for the preparation of brivaracetam
US11400074B1 (en) * 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US20240343689A1 (en) * 2021-08-16 2024-10-17 Optimus Drugs Private Limited Synthesis of brivaracetam
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
CN114989061A (zh) * 2022-08-03 2022-09-02 江苏同禾药业有限公司 一种布瓦西坦的制备方法
CN115466233B (zh) * 2022-09-28 2024-08-23 合肥立方制药股份有限公司 一种布瓦西坦中间体(r)-4-丙基-二氢呋喃-2-酮的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
AU2002329233B2 (en) * 2001-08-10 2007-08-16 Ucb Pharma Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
JP4658937B2 (ja) 2003-09-24 2011-03-23 ユセベ ファルマ ソシエテ アノニム 2−オキソ−1−ピロリジン誘導体の製造方法
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
CA2620243C (en) 2005-09-15 2015-01-20 Ucb Pharma, S.A. 4-substituted pyrrolidin-2-ones and their use
AU2006322297A1 (en) 2005-12-07 2007-06-14 Ucb Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
KR20070081959A (ko) 2006-02-14 2007-08-20 (주)지앤테크 은이 포함된 정수기용 필터
KR100846419B1 (ko) 2007-08-10 2008-07-15 한국과학기술원 프레가발린의 신규한 제조 방법
KR100915671B1 (ko) * 2007-08-14 2009-09-04 한국과학기술원 치환된 γ-부티로락톤의 광학선택적 제조방법
WO2010111622A2 (en) * 2009-03-27 2010-09-30 Codexis, Inc. Amidases and methods of their use
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
WO2012140504A1 (en) 2011-04-11 2012-10-18 Rubhana Raqib Therapeutic compounds
US20140228579A1 (en) 2013-02-14 2014-08-14 Brock Unviersity Method for the catalytic reduction of acid chlorides and imidoyl chlorides
CN103819389A (zh) * 2014-02-17 2014-05-28 北京博泽德润医药科技开发有限公司 一种左乙拉西坦制备方法
CA2984832A1 (en) 2015-05-25 2016-12-01 Esteve Quimica S.A. Processes to produce brivaracetam
RS62472B1 (sr) 2015-11-03 2021-11-30 UCB Biopharma SRL Postupak pripreme brivaracetama
WO2018220646A1 (en) 2017-05-29 2018-12-06 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereof
WO2019087172A1 (en) 2017-12-19 2019-05-09 Glenmark Pharmaceuticals Limited Process for preparation of brivaracetam
WO2020148731A1 (en) 2019-01-19 2020-07-23 Stereokem Pvt. Ltd. Process for preparation of brivaracetam intermediates and use thereof

Also Published As

Publication number Publication date
EP3302441A1 (en) 2018-04-11
US11673862B2 (en) 2023-06-13
JP2018523633A (ja) 2018-08-23
US10221134B2 (en) 2019-03-05
US20190152909A1 (en) 2019-05-23
US20240199541A9 (en) 2024-06-20
EP3302441A4 (en) 2019-01-09
EP3302441B1 (en) 2023-12-13
HRP20240027T1 (hr) 2024-04-26
BR112017025266A2 (pt) 2018-08-07
US20190152908A1 (en) 2019-05-23
IL255880A (en) 2018-01-31
US20180155284A1 (en) 2018-06-07
EP3302441C0 (en) 2023-12-13
CA2984832A1 (en) 2016-12-01
JP6872500B2 (ja) 2021-05-19
KR102630456B1 (ko) 2024-01-29
WO2016191435A1 (en) 2016-12-01
ES2965746T3 (es) 2024-04-16
US12221413B2 (en) 2025-02-11
HUE064612T2 (hu) 2024-04-28
KR20180012788A (ko) 2018-02-06
PL3302441T3 (pl) 2024-05-20
IL255880B (en) 2021-02-28
MX2017015133A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
MX380263B (es) Procesos para producir brivaracetam.
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
EA202092435A3 (ru) Моноклональные антитела против bcma
CA3015585C (en) Pth prodrugs
JO3613B1 (ar) معزز واستخداماته
PH12016501763B1 (en) Multispecific antibodies
HUE057926T2 (hu) Eljárás tiokarbonátok elõállítására
DK3142785T3 (da) Fremgangsmåde til fremstilling af alkenoler og anvendelse deraf til fremstilling af 1,3-butadien
DK3390354T3 (da) Fremgangsmåde til tilvejebringelse af carbondioxid til syntese af urea
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
BR112019020338A8 (pt) Composição para produção de tagatose, e, método de produção de tagatose
DK3230236T3 (da) Fremgangsmåde til fremstilling af 1,3-butadien fra 1,3-butandiol
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
DK3592723T3 (da) Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2016015298A (es) Inhibidores de nampt y metodos.
CL2016001505A1 (es) Proceso para la producción de gas de síntesis de amoníaco.
MX382631B (es) Proceso para la preparacion de derivados dihidroisoxazol.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
EP3177280A4 (en) Synthesis of 2,2,2-trifluoroethanethiol
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
MX380241B (es) Proceso para preparar 3-cloro-2-vinilfenol.
DK3493849T3 (en) New uses of n, n-bis-2-mercaptoethyl isophthalamide